Novo nordisk a/s NVO.US Overview
NVO AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
NVO Current Performance
-2.49%
Novo nordisk a/s
-1.83%
Avg of Sector
-0.40%
S&P500
NVO Key Information
NVO Revenue by Segments
Browsing restrictions can be lifted for a fee.
NVO Net Income
Browsing restrictions can be lifted for a fee.
NVO Cash Flow
Browsing restrictions can be lifted for a fee.
NVO Profit Margin
Browsing restrictions can be lifted for a fee.
NVO PE Ratio River
Browsing restrictions can be lifted for a fee.
NVO Financial Forecast
Browsing restrictions can be lifted for a fee.
NVO Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
NVO Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Price of NVO
NVO FAQ
When is NVO's latest earnings report released?
The most recent financial report for Novo nordisk a/s (NVO) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NVO's short-term business performance and financial health. For the latest updates on NVO's earnings releases, visit this page regularly.
Where does NVO fall in the P/E River chart?
According to historical valuation range analysis, Novo nordisk a/s (NVO)'s current price-to-earnings (P/E) ratio is 19, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of NVO?
According to the latest financial report, Novo nordisk a/s (NVO) reported an Operating Profit of 38.79B with an Operating Margin of 49.68% this period, representing a growth of 21.81% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is NVO's revenue growth?
In the latest financial report, Novo nordisk a/s (NVO) announced revenue of 78.09B, with a Year-Over-Year growth rate of 19.49%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does NVO have?
As of the end of the reporting period, Novo nordisk a/s (NVO) had total debt of 118.72B, with a debt ratio of 0.24. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does NVO have?
At the end of the period, Novo nordisk a/s (NVO) held Total Cash and Cash Equivalents of 38.94B, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does NVO go with three margins increasing?
In the latest report, Novo nordisk a/s (NVO) achieved the “three margins increasing” benchmark, with a gross margin of 83.5%%, operating margin of 49.68%%, and net margin of 37.2%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NVO's profit trajectory and future growth potential.
Is NVO's EPS continuing to grow?
According to the past four quarterly reports, Novo nordisk a/s (NVO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 6.54. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of NVO?
Novo nordisk a/s (NVO)'s Free Cash Flow (FCF) for the period is 11.17B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 91.25% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of NVO?
The latest valuation data shows Novo nordisk a/s (NVO) has a Price-To-Earnings (PE) ratio of 19 and a Price/Earnings-To-Growth (PEG) ratio of 5.8. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.